TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ADAS - Cognitive subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trail Making Test part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in vaginal pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: median neutrophil count on nasal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sneezing improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal congestion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in skin symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: grade 2-4 anemia
Endpoint domain: Adverse events/effects
Primary endpoint: Cost-effectiveness of minocycline/rifampin catheters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost savings with minocycline/rifampin catheters
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pathological complete responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dworak grade 4 tumour regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of discussions about psychosocial issues
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved diagnosis of normal and abnormal secondary palate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved diagnosis of normal corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Grade 2 to 4 mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: EXTEM area under the velocity curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: red blood cell folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cord blood folate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antibiotic-associated diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: acute coronary syndrome averted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: event-free survivor
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decrease in IL-6 and TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CTV increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compression depth performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: active extension and arc of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan Hand Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical response defined by a decrease of at least 70 points in the CDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: suppression of angiotensin II levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reduction in renal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postoperative pain scores on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the HOME T-score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in early SD from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Histologic assessment improvement in epidermal and dermal layers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subjective preference for HiRes 120/Harmony processor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with the Harmony processor
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Factor VII (FVIIc‐%) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibrinogen levels (Fb‐g/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PAI-1 activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood pressure measurement correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vte (Tidal Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEEP (Positive End-Expiratory Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural checklist performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hand-washing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dry skin incidence
Endpoint domain: Adverse events/effects
Primary endpoint: average urine flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time taken from induction to successful laryngeal mask insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditions for insertion of the laryngeal mask airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of anesthetic agents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median polypectomy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cecal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall colonoscopy time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cold-induced morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold two-point decrease in pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall decline in VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin consumption to maintain target glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost of obtaining a survivor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of treating postoperative complications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EMG activation of diaphragm and external intercostal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gag-specific CD8+ T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte count post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: shoulder pain incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unassisted walking within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative vomiting incidence
Endpoint domain: Adverse events/effects
Primary endpoint: 2-month mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: procedural adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Her2/neu expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative days until the patient began to eat normally
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative days on which analgesic administration was necessary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater reliability for shoulder tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychiatric Inventory (NPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geriatric Depression Scale (GDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: all-cause deaths
Endpoint domain: Mortality/survival
Primary endpoint: Caregiver competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of syncopal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of presyncopal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measures (SF-36 scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brachial systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urine NGAL levels 2 h postoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urine IL-18 levels 2 h postoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postcircumcision pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Activity (GA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric Symptomatology (GSW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspeptic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Two-hour postmeal plasma glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median fasting duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in the glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: area under insulin curves for the first 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: arm and hand motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported motor ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 8-oxodG excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall monthly vertigo attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time taken for placental delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aPWV (aortic pulse wave velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to discontinuation due to lack of tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: stimulus detection improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to readiness for discharge from the post anaesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall confirmed hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Self-monitored FBG targets achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satisfaction with esthetic appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recurrent ischemic stroke risk
Endpoint domain: Mortality/survival
Primary endpoint: blood leukocyte and neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum IgG and IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percent of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: withdrawal due to disease progression
Endpoint domain: Adverse events/effects
Primary endpoint: AF recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported hearing aid use time accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression level of MMP2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression level of MMP9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression level of TIMP2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: deterioration-free survival
Endpoint domain: Mortality/survival
Primary endpoint: serum P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ca × P product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDnA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1,3,5,9-year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Good functional outcomes (mRS 0-2) at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of functional dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: defect fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left atrial ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of ventilator days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean objective acne score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of severe/moderate acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Intravascular uptake of contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to psychosis
Endpoint domain: Mortality/survival
Primary endpoint: Remission from at-risk mental state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effect of saffron extract in Alzheimer's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival free of subsequent hospitalization for cardiac cause
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of 50% or more in Roland function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: HDL-C improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: 3-year primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: lower depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lower weekly probability of being in a major depressive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher weekly probabilities of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean attitude scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean belief scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: New vertebral fractures (VFx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severe vertebral fractures (VFx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Macular attachment at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical care score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical management score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year risk of CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative risk of PCa diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Biopsy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Yield of PCa on biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: C‐IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Femoral artery stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sVCAM‐1, sICAM‐1, and vWF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absolute oral bioavailability of selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance of selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating tumor cell (CTC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity for NSCLC diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in urinary protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Function of left atrium relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of postendodontic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median time to empiric treatment start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myoclonic movements
Endpoint domain: Adverse events/effects
Primary endpoint: recovery time after etomidate administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma glucose AUC2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean plasma insulin AUC2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: implicit memory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of geriatric conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life preservation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response to hypnotherapy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients PCR-negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean residual HBV DNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in meaningful activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: CFS grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days in hospital initiating therapy
Endpoint domain: Resource use
Endpoint subdomain: Hospital